Butler NJ, Furtado JM, Winthrop KL, Smith JR. Ocular toxoplasmosis II: clinical features, pathology and management. Clinical & experimental ophthalmology 2013;41:95- 108.
Bonfioli AA, Orefice F. Toxoplasmosis. Seminars in ophthalmology 2005;20:129- 41.
Englander M, Young LH. Ocular toxoplasmosis: advances in detection and treatment. International ophthalmology clinics 2011;51:13-23.
Stanford MR, Gilbert RE. Treating ocular toxoplasmosis: current evidence. Memorias do Instituto Oswaldo Cruz 2009;104:312-5.
Stanford MR, See SE, Jones LV, Gilbert RE. Antibiotics for toxoplasmic retinochoroiditis: an evidence-based systematic review. Ophthalmology 2003;110:926-31; quiz 31-2.
Balaskas K, Vaudaux J, Boillat-Blanco N, Guex- Crosier Y. Azithromycin versus Sulfadiazine and Pyrimethamine for non-vision-threatening toxoplasmic retinochoroiditis: a pilot study. Medical science monitor: international medical journal of experimental and clinical research 2012;18:CR296-302.
Kim SJ, Scott IU, Brown GC, et al. Interventions for toxoplasma retinochoroiditis: a report by the american academy of ophthalmology. Ophthalmology 2013;120:371-8.
Colin J, Harie JC. [Presumed toxoplasmic chorioretinitis: comparative study of treatment with pyrimethamine and sulfadiazine or clindamycin]. Journal francais d'ophtalmologie 1989;12:161-5.
Soheilian M, Sadoughi MM, Ghajarnia M, et al. Prospective randomized trial of trimethoprim/sulfamethoxazole versus pyrimethamine and sulfadiazine in the treatment of ocular toxoplasmosis. Ophthalmology 2005;112:1876-82.
Bosch-Driessen LH, Verbraak FD, Suttorp- Schulten MS, et al. A prospective, randomized trial of pyrimethamine and azithromycin vs pyrimethamine and sulfadiazine for the treatment of ocular toxoplasmosis. American journal of ophthalmology 2002;134:34- 40.
Soheilian M, Ramezani A, Azimzadeh A, et al. Randomized trial of intravitreal clindamycin and dexamethasone versus pyrimethamine, sulfadiazine, and prednisolone in treatment of ocular toxoplasmosis. Ophthalmology 2011;118:134-41.
Lasave AF, Diaz-Llopis M, Muccioli C, Belfort R, Jr., Arevalo JF. Intravitreal clindamycin and dexamethasone for zone 1 toxoplasmic retinochoroiditis at twenty-four months. Ophthalmology 2010;117:1831-8.
Holland GN, Crespi CM, ten Dam-van Loon N, et al. Analysis of recurrence patterns associated with toxoplasmic retinochoroiditis. American journal of ophthalmology 2008;145:1007-13.
Silveira C, Belfort R, Jr., Muccioli C, et al. The effect of long-term intermittent trimethoprim/sulfamethoxazole treatment on recurrences of toxoplasmic retinochoroiditis. American journal of ophthalmology 2002;134:41-6.
O'Connor GR, Frenkel JK. Editorial: Dangers of steroid treatment in toxoplasmosis. Periocular injections and systemic therapy. Archives of ophthalmology 1976;94:213.
Martinez CE, Zhang D, Conway MD, Peyman GA. Successful management of ocular toxoplasmosis during pregnancy using combined intraocular clindamycin and dexamethasone with systemic sulfadiazine. International ophthalmology 1998;22:85-8.
Adan A, Mateo C, Navarro R, Bitrian E, Casaroli-Marano RP. Intravitreal bevacizumab (avastin) injection as primary treatment of inflammatory choroidal neovascularization. Retina 2007;27:1180-6.
Ben Yahia S, Herbort CP, Jenzeri S, et al. Intravitreal bevacizumab (Avastin) as primary and rescue treatment for choroidal neovascularization secondary to ocular toxoplasmosis. International ophthalmology 2008;28:311-6.
Rouvas A, Petrou P, Douvali M, et al. Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization. Retina 2011;31:871-9.
Benevento JD, Jager RD, Noble AG, et al. Toxoplasmosis-associated neovascular lesions treated successfully with ranibizumab and antiparasitic therapy. Archives of ophthalmology 2008;126:1152-6.
Mauget-Faysse M, Mimoun G, Ruiz-Moreno JM, et al. Verteporfin photodynamic therapy for choroidal neovascularization associated with toxoplasmic retinochoroiditis. Retina 2006;26:396-403.
Rishi P, Venkataraman A, Rishi E. Combination photodynamic therapy and bevacizumab for choroidal neovascularization associated with toxoplasmosis. Indian journal of ophthalmology 2011;59:62-4.
Adan A, Giralt J, Alvarez G, et al. Pars plana vitrectomy for vitreoretinal complications of ocular toxoplasmosis. European journal of ophthalmology 2009;19:1039-43.
Bovey EH. Usefulness of vitrectomy in the treatment of ocular toxoplasmosis. International journal of medical sciences 2009;6:139.
Sauer A, Pfaff AW, Villard O, et al. Interleukin 17A as an effective target for anti-inflammatory and antiparasitic treatment of toxoplasmic uveitis. The Journal of infectious diseases 2012;206:1319-29.
